Coravog-R 0.2/1

Coravog-R 0.2/1 mg(Voglibose 0.2 mg + Repaglinide 1 mg) Tablet is a well-balanced combination therapy used in the management of Type 2 Diabetes Mellitus, particularly for patients who struggle with high blood sugar levels after meals. It brings together voglibose and repaglinide—two proven agents that work in a complementary way to provide better control over postprandial glucose.This formulation is designed to act quickly around mealtime while also reducing the absorption of carbohydrates, helping maintain more stable blood sugar levels throughout the day. It is especially helpful for patients who need targeted control of post-meal spikes along with overall glycemic balance. Repaglinide is a meglitinide analog that increases the amount of insulin released by the pancreas. Voglibose is an alpha-glucosidase inhibitor that inhibits the intestinal enzymes that cause the breakdown of complex sugars into simple sugars such as glucose.  

How does Coravog-R  0.2/1 mg (Voglibose 0.2 mg + Repaglinide 1 mg) work?

Repaglinide 1 mg (Meglitinide): Acts as a rapid-acting insulin secretagogue. It closes ATP-sensitive potassium channels in pancreatic \(\beta \)-cells, causing depolarization and calcium influx, which triggers immediate insulin release, especially after meals.

Voglibose 0.2 mg (\(\alpha \)-glucosidase inhibitor): Reversibly inhibits enzymes (alpha-glucosidase) in the intestinal brush border. This action delays the digestion and absorption of complex carbohydrates, reducing post-prandial hyperglycemia (blood sugar spikes)

Clinical Benefits 

Effective Postprandial Glucose Control: The combination reduces high blood sugar levels immediately following meals (postprandial hyperglycemia).

Dual Mechanism Action: Repaglinide stimulates the pancreas to release insulin, while voglibose slows down the breakdown of complex carbohydrates in the intestine, preventing sharp glucose spikes.

Reduced Complication Risks: By achieving better overall glycemic control, this combination helps lower the risk of long-term diabetes-related complications such as neuropathy, retinopathy, and kidney damage.

Better Management Than Single Therapy: It is particularly useful when monotherapy with either agent is not sufficient, providing better glycemic control than either medication alone.

Dosage & Administration

To be taken as directed by the physician.

 It is generally recommended to take the tablet before meals for best results.

Disclaimer

Results may vary from patient to patient. This product does not cure diabetes but helps in its effective management when used as prescribed. Please consult your healthcare provider for proper diagnosis and treatment.